Novartis ($NVS) was last year's biggest R&D spender in the pharma industry. Now, the company is warning U.K. officials that, unless they change their ways, Novartis will be spending less and less of its research billions in that country. Report
USP <232> Elemental Impurities—Limits and <233> Elemental Impurities—Procedures are close to being adopted. But the monographs will not provide specific sample preparation methods. This article outlines three case studies for sample preparation. Download Today.
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!